UNSPSC 51162709: Cistinexine

This classification denotes a mucolytic agent and expectorant with the molecular formula C50H60Br4N6O6S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 62VR67FK8E, chemically known as 2-oxa-7,8-dithia-4,11-diazadodecan-12-oic acid, 5,10-bis(((2,4-dibromo-6-((cyclohexylmethylamino)methyl)phenyl)amino)carbonyl)-3-oxo-1-phenyl-, phenylmethyl ester, (r-(r*,r*))- but more generally known as cistinexine, which bears US NIH Compound Identifier 65644.

UNSPSC 51162709 Cistinexine, a Commodity code, does not align with recent state and local procurement activity tagged under it. The two most recent opportunities—Seminole County's naloxone and drug deactivation systems purchase and the Minnesota Multistate Cooperative Purchasing Alliance's generic pharmaceuticals and OTC products RFP—involve naloxone, pharmaceutical distribution, and medical supplies, none of which match the narrow chemical or pharmaceutical compound scope implied by the Cistinexine code name. The mismatch suggests either a cataloging error in the source data or a drift in how issuing bodies are applying the code to broader health-supply purchasing. State and local buyers appear to be using this code slot to solicit emergency-response medications and generic pharmaceutical products through both direct county procurement and cooperative purchasing vehicles, but the code's nominal definition does not reliably describe the work actually being bought.

Geographically, recent activity centers on Florida and Minnesota, with the Minnesota cooperative purchasing agreement extending to Oregon and other participating state and local facilities. Seminole County, Florida released an IFB (Solicitation Number IFB60459723LAS) on June 30, 2026 for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, with bids due July 26, 2023. The Minnesota Department of Administration's Office of State Procurement issued an RFP (Solicitation Number S1070000015802) on January 20, 2026 for generic multi-source pharmaceuticals and OTC products through authorized wholesalers, with proposals due March 26, 2026 and contract effectiveness July 1, 2026. Neither opportunity identifies explicit set-aside restrictions, though both require standard compliance certifications including drug-free workplace, E-Verify, and FDA or cGMP compliance as applicable.